$2.17
1.36% yesterday
Nasdaq, Aug 01, 10:00 pm CET
ISIN
US74754R1032
Symbol
QLGN

Qualigen Therapeutics Inc Stock price

$2.17
-1.15 34.64% 1M
-1.33 38.00% 6M
-2.04 48.46% YTD
-9.59 81.54% 1Y
-205.33 98.95% 3Y
-2,737.83 99.92% 5Y
-481,247.83 100.00% 10Y
-619,997.83 100.00% 20Y
Nasdaq, Closing price Fri, Aug 01 2025
-0.03 1.36%
ISIN
US74754R1032
Symbol
QLGN
Industry

Key metrics

Basic
Market capitalization
$3.6m
Enterprise Value
$4.4m
Net debt
$810.0k
Cash
$30.0k
Shares outstanding
1.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
118.3
Financial Health
Equity Ratio
57.2%
Return on Equity
-
ROCE
-16,275.3%
ROIC
-626.2%
Debt/Equity
28.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | -
EBIT
$-6.5m | $-11.6m
Net Income
$-6.9m | $-1.2m
Free Cash Flow
$-7.1m
Growth (TTM | estimate)
Revenue
-100.0% | -
EBITDA
- | -
EBIT
35.1% | -
Net Income
40.8% | -
Free Cash Flow
15.7%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-4.7
FCF per Share
$-4.4
Short interest
1.5%
Employees
4
Rev per Employee
-
Show more

Is Qualigen Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,028 stocks worldwide.

Qualigen Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Qualigen Therapeutics Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Qualigen Therapeutics Inc forecast:

Buy
86%
Hold
14%

Financial data from Qualigen Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.64 5.64
9% 9%
-
- Research and Development Expense 0.91 0.91
80% 80%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -6.51 -6.51
35% 35%
-
Net Profit -6.90 -6.90
41% 41%
-

In millions USD.

Don't miss a Thing! We will send you all news about Qualigen Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Qualigen Therapeutics Inc Stock News

Neutral
GlobeNewsWire
5 days ago
Carlsbad, CA, July 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or the "Company"), a life sciences company focused on developing platform treatments for adult and pediatric cancers with the potential for orphan drug designations, today announced that it has entered into definitive securities purchase agreements with several institutional and accredited inve...
Neutral
GlobeNewsWire
2 months ago
CARLSBAD, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") on May 19, 2025 (the "Notice"). The Notice indicated that the Nasdaq Hearings Panel (the “Panel”) will consider the Company's failu...
Neutral
GlobeNewsWire
3 months ago
CARLSBAD, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) on April 24, 2025 (the "Notice"). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c) (the...

Company Profile

Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS™. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company is headquartered in Los Angeles, CA.

Head office United States
CEO Kevin Richardson
Employees 4
Founded 2004
Website qlgntx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today